Advances in IL–15–Based Cancer Immunotherapy and Divergent Immunological Effects of IL–2 and IL–15 Signaling via the Shared IL–2Rβγ Receptor
T-cell fate decisions, and discusses key opportunities and challenges for translating IL-15-mediated immune enhancement into durable clinical benefit.
Authors
- Huiquan Gao
- Gang Wu (ORCID: https://orcid.org/0000-0001-9854-2817)
- Jinfang Li
- Fuxin Zhou
- Wenxin He
- Zhixin Zhang
- Ziyong Liu
- Qinqin Jiang
- Shubo Wang
- Tao Ma
Institutions
- Qingdao University (CN)
- Tongji University (CN)
- University of Freiburg (DE)
- University Medical Center Freiburg (DE)
- Yuhuangding Hospital (CN)
- 117th Hospital of People's Liberation Army (CN)
- 174th hospital of the People's Liberation Army (CN)
- Affiliated Hospital of Qingdao University (CN)
- Institut thématique Génétique, génomique et bioinformatique (FR)
- Weihai Municipal Hospital (CN)
- Shanghai Pulmonary Hospital (CN)
- Weihai Maternal and Child Health Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-04-10
- DOI
- https://doi.org/10.3389/fimmu.2026.1791059
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.00